Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1993 1
1996 1
1997 3
2001 2
2002 1
2003 1
2005 1
2006 1
2007 1
2009 1
2010 1
2011 1
2012 4
2013 6
2014 3
2015 3
2016 5
2018 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypoalphalipoproteinemia, primary, 2"
Page 1
ABCA1 and atherosclerosis.
Soumian S, Albrecht C, Davies AH, Gibbs RG. Soumian S, et al. Vasc Med. 2005 May;10(2):109-19. doi: 10.1191/1358863x05vm593ra. Vasc Med. 2005. PMID: 16013195 Review.
PPAR agonists like glitazones and ABCA1 protein stabilization could potentially modify the clinical progression of atherosclerotic lesions....
PPAR agonists like glitazones and ABCA1 protein stabilization could potentially modify the clinical progression of atherosclerotic le …
A machine learning approach to personalized predictors of dyslipidemia: a cohort study.
Gutiérrez-Esparza G, Pulido T, Martínez-García M, Ramírez-delReal T, Groves-Miralrio LE, Márquez-Murillo MF, Amezcua-Guerra LM, Vargas-Alarcón G, Hernández-Lemus E. Gutiérrez-Esparza G, et al. Front Public Health. 2023 Sep 20;11:1213926. doi: 10.3389/fpubh.2023.1213926. eCollection 2023. Front Public Health. 2023. PMID: 37799151 Free PMC article.
Our primary objective was to identify potential factors associated with different types of dyslipidemia in both men and women. ...To facilitate feature selection, we applied the Variable Importance Measures (VIM) of Random Forest (RF), XGBoost, and Gradient Boosting …
Our primary objective was to identify potential factors associated with different types of dyslipidemia in both men and women. ...To …
ABC transporters, atherosclerosis and inflammation.
Fitzgerald ML, Mujawar Z, Tamehiro N. Fitzgerald ML, et al. Atherosclerosis. 2010 Aug;211(2):361-70. doi: 10.1016/j.atherosclerosis.2010.01.011. Epub 2010 Jan 21. Atherosclerosis. 2010. PMID: 20138281 Free PMC article. Review.
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
Ronsein GE, Reyes-Soffer G, He Y, Oda M, Ginsberg H, Heinecke JW. Ronsein GE, et al. Mol Cell Proteomics. 2016 Mar;15(3):1083-93. doi: 10.1074/mcp.M115.054528. Epub 2015 Dec 14. Mol Cell Proteomics. 2016. PMID: 26667175 Free PMC article.
However, a paradoxical marked reduction in HDL-C and HDL's major protein, apolipoprotein A-I, is a complication of fenofibrate in combination with rosiglitazone, an insulin-sensitizing agent. Risk factors for this condition, termed hypoalphalipoproteinemia, have yet to be …
However, a paradoxical marked reduction in HDL-C and HDL's major protein, apolipoprotein A-I, is a complication of fenofibrate in combinatio …
Tangier disease.
Mentis SW. Mentis SW. Anesth Analg. 1996 Aug;83(2):427-9. doi: 10.1097/00000539-199608000-00040. Anesth Analg. 1996. PMID: 8694332 No abstract available.
Hypoalphalipoproteinemia: postprandial response of subjects with preprandial normotriglyceridemia and hypertriglyceridemia to various diets.
Edelstein C, Fredenrich C, Schuelke JC, Jensen WE, Sitrin M, Iverius PH, Scanu AM. Edelstein C, et al. Metabolism. 1993 Feb;42(2):247-57. doi: 10.1016/0026-0495(93)90043-n. Metabolism. 1993. PMID: 8474323
The effect of a single oral fat meal (60 g fat/m2 body surface area) enriched in either saturated (SFA) or polyunsaturated ([PUFA] omega-6 or omega-3) fatty acids on postprandial lipoprotein levels was studied in four men with primary hypoalphalipoproteinemia (HP) a …
The effect of a single oral fat meal (60 g fat/m2 body surface area) enriched in either saturated (SFA) or polyunsaturated ([PUFA] omega-6 o …
Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate.
Meco JF, Vila R, Pujol R, Bros R, Domènech P, Fiol C, Pintó X. Meco JF, et al. J Cardiovasc Pharmacol. 2001 Aug;38(2):250-8. doi: 10.1097/00005344-200108000-00011. J Cardiovasc Pharmacol. 2001. PMID: 11483875
We studied the effect of increasing HDLc on endothelial function in patients with coronary artery disease (CAD) and isolated low HDLc (HDLc) <0.91 mM, low-density lipoprotein cholesterol (LDLc) <4.1 mM, and triglycerides <2.8 mM. Flow-mediated endothelium-dependen …
We studied the effect of increasing HDLc on endothelial function in patients with coronary artery disease (CAD) and isolated low HDLc (HDLc) …
Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement.
Shamburek RD, Bakker-Arkema R, Auerbach BJ, Krause BR, Homan R, Amar MJ, Freeman LA, Remaley AT. Shamburek RD, et al. J Clin Lipidol. 2016 Mar-Apr;10(2):356-67. doi: 10.1016/j.jacl.2015.12.007. Epub 2015 Dec 23. J Clin Lipidol. 2016. PMID: 27055967 Free PMC article.
METHODS: rhLCAT (ACP-501) was infused intravenously over 1 hour on 3 occasions in a dose optimization phase (0.3, 3.0, and 9.0 mg/kg), then 3.0 or 9.0 mg/kg every 1 to 2 weeks for 7 months in a maintenance phase. Plasma lipoproteins, lipids, LCAT levels, and several measur …
METHODS: rhLCAT (ACP-501) was infused intravenously over 1 hour on 3 occasions in a dose optimization phase (0.3, 3.0, and 9.0 mg/kg), then …
Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study.
Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, Muiesan ML, Agabiti-Rosei E. Sirtori CR, et al. Circulation. 2001 Apr 17;103(15):1949-54. doi: 10.1161/01.cir.103.15.1949. Circulation. 2001. PMID: 11306522 Free article. Clinical Trial.
METHODS AND RESULTS: Twenty-one A-I(M) carriers were compared with age- and sex-matched control subjects from the same kindred and with 2 series of matched subjects with primary hypoalphalipoproteinemia (HA). ...
METHODS AND RESULTS: Twenty-one A-I(M) carriers were compared with age- and sex-matched control subjects from the same kindred and with 2 …
33 results